CAMZYOS(Mavacamten) was recently approved in the European Union, following its approval in the U.S. and other markets worldwide, and is the first and only cardiac myosin inhibitor approved to treat adult patients with symptomatic obstructive hypertrophic cardiomyopathy(HCM).
Mavacamten is a first-in-class, targeted inhibitor of cardiac myosin, reduces the number of myosin-actin cross-bridges and thus decreases excessive contractility characteristic of HCM.